Key Recognition Details
Biocon Limited (BSE: 532523, NSE: BIOCON) has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by Science magazine. This marks the company's 15th consecutive year on this list, having first appeared in 2012.
Recognition Attributes
The company was specifically recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values.
Management Commentary
Shreehas Tambe, CEO and Managing Director of Biocon, stated: "I am proud that Biocon has been recognized by Science magazine as one of the world's Top 20 biopharmaceutical employers for the 15th consecutive year. This recognition reflects the talent, passion and commitment of our people. At Biocon, we believe that great science begins with great people. As we advance our ambition to become a fully integrated global medicines company, we remain committed to fostering a culture of innovation, excellence and collaboration enabling us to make a meaningful difference to patients worldwide."
Workforce Diversity
Biocon's workforce includes employees representing 37 nationalities across more than 60 cities worldwide.
Survey Methodology
The Science and Science Careers' 2026 Top Employers Survey polled employees in relevant industries to determine the 20 best employers based on 24 characteristics covering categories such as corporate image, financial prowess, leadership and direction, and work culture/environment. The findings are based on approximately 5,100 completed surveys, with respondents primarily from North America (71%), Europe (19%), and Asia/Pacific Rim (6%). Survey responses were analyzed by U.S.-based The Brighton Consulting Group.
Company Background
Biocon Limited is a global biopharmaceutical company headquartered in Bengaluru, India, focused on providing affordable, life-changing medicines to patients worldwide. The company has commercialized 12 biosimilar products and 30+ generic formulations globally, with a pipeline of 20+ biosimilar assets, GLP-1 peptides, and other complex generics. Biocon operates in more than 120 countries with seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees.
Financial Impact
No financial impact quantified in the disclosure.